CA2787114A1 - Methods of treating meibomian gland dysfunction - Google Patents

Methods of treating meibomian gland dysfunction Download PDF

Info

Publication number
CA2787114A1
CA2787114A1 CA2787114A CA2787114A CA2787114A1 CA 2787114 A1 CA2787114 A1 CA 2787114A1 CA 2787114 A CA2787114 A CA 2787114A CA 2787114 A CA2787114 A CA 2787114A CA 2787114 A1 CA2787114 A1 CA 2787114A1
Authority
CA
Canada
Prior art keywords
compound
halogen
nhcor
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2787114A
Other languages
English (en)
French (fr)
Inventor
James T. Dalton
Jeetendra Eswaraka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of CA2787114A1 publication Critical patent/CA2787114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2787114A 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction Abandoned CA2787114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29396610P 2010-01-11 2010-01-11
US61/293,966 2010-01-11
PCT/US2011/020871 WO2011085385A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Publications (1)

Publication Number Publication Date
CA2787114A1 true CA2787114A1 (en) 2011-07-14

Family

ID=44259000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787114A Abandoned CA2787114A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Country Status (10)

Country Link
US (1) US8791158B2 (https=)
EP (1) EP2523556A4 (https=)
JP (1) JP2013516501A (https=)
KR (1) KR20120115380A (https=)
CN (1) CN103002737A (https=)
AU (1) AU2011203832A1 (https=)
CA (1) CA2787114A1 (https=)
MX (1) MX2012008110A (https=)
RU (1) RU2012134351A (https=)
WO (1) WO2011085385A1 (https=)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8523928B2 (en) 2006-05-15 2013-09-03 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8617229B2 (en) 2006-05-15 2013-12-31 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8628504B2 (en) 2005-07-18 2014-01-14 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US8632578B2 (en) 2006-05-15 2014-01-21 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8685073B2 (en) 2005-07-18 2014-04-01 Tearscience, Inc. Apparatus for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9216028B2 (en) 2005-07-18 2015-12-22 Tearscience, Inc. Apparatuses for treatment of meibomian glands
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9913678B2 (en) 2005-07-18 2018-03-13 Tearscience, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RU2567829C1 (ru) * 2014-10-22 2015-11-10 Елизавета Геннадьевна Полунина Способ оценки морфофункционального состояния мейбомиевых желез - биометрия мейбомиевых желез
KR101714710B1 (ko) 2015-09-17 2017-03-10 고려대학교 산학협력단 마이봄샘 압출기
CN114469991A (zh) 2016-04-14 2022-05-13 阿祖拉眼科有限公司 用于治疗睑板腺功能障碍的二硫化硒组合物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US20230168157A1 (en) * 2021-11-29 2023-06-01 Petróleo Brasileiro S.A. - Petrobras System and method for evaluation of the deposition in tubes of the furnaces of a delayed coking unit
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) * 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7253210B2 (en) 2002-10-15 2007-08-07 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
CA2476657A1 (en) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Haloacetamide and azide substituted compounds and methods of use thereof
EP1487458B1 (en) * 2002-02-28 2011-11-16 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
GEP20074209B (en) 2002-02-28 2007-10-10 , Multi-substitued selective androgen receptor modulators and methods of use thereof
GEP20074191B (en) * 2002-06-17 2007-09-10 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
JP2006518328A (ja) * 2002-10-15 2006-08-10 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 複素環選択的アンドロゲン受容体調節剤及びその使用方法
US20040265916A1 (en) * 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
AU2003287075A1 (en) * 2002-10-15 2004-05-04 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2457892A1 (en) * 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
JP2006516286A (ja) 2003-01-22 2006-06-29 ジーティーエックス・インコーポレイテッド Sarmによる女性のアンドロゲン減少に関連する病気の治療
CA2522874A1 (en) * 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20070082017A1 (en) * 2004-01-10 2007-04-12 Tseng Scheffer C Lipid compositions and methods of use
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20130034562A1 (en) * 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
ATE552235T1 (de) 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
JP4899625B2 (ja) * 2006-05-12 2012-03-21 スズキ株式会社 鞍乗型不整地走行車両
PT2038252T (pt) * 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
CA2658098A1 (en) * 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
HRP20180500T1 (hr) * 2007-09-11 2018-06-01 Gtx, Inc. Kristalni polimorf selektivnih modulatora androgena (r) ili (s)-n-(4-cijano-3-(trifluorometil)fenil)-3-(4-cijanofenoksi)-2-hidroksi-2-metilpropanamida
US7968603B2 (en) * 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216028B2 (en) 2005-07-18 2015-12-22 Tearscience, Inc. Apparatuses for treatment of meibomian glands
US9913678B2 (en) 2005-07-18 2018-03-13 Tearscience, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8628504B2 (en) 2005-07-18 2014-01-14 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US8685073B2 (en) 2005-07-18 2014-04-01 Tearscience, Inc. Apparatus for treating meibomian gland dysfunction
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US10905898B2 (en) 2005-07-18 2021-02-02 Tearscience, Inc. Methods and apparatuses for treating gland dysfunction
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US10376273B2 (en) 2005-07-18 2019-08-13 Tearscience, Inc. Methods and apparatuses for treatment of meibomian glands
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8523928B2 (en) 2006-05-15 2013-09-03 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8617229B2 (en) 2006-05-15 2013-12-31 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8632578B2 (en) 2006-05-15 2014-01-21 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices

Also Published As

Publication number Publication date
US8791158B2 (en) 2014-07-29
JP2013516501A (ja) 2013-05-13
MX2012008110A (es) 2012-10-03
KR20120115380A (ko) 2012-10-17
RU2012134351A (ru) 2014-02-20
US20110172302A1 (en) 2011-07-14
EP2523556A1 (en) 2012-11-21
CN103002737A (zh) 2013-03-27
WO2011085385A1 (en) 2011-07-14
AU2011203832A1 (en) 2012-08-23
EP2523556A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
US8791158B2 (en) Methods of treating meibomian gland dysfunction
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
EP3078376B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CN101299920A (zh) 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤
CN102781436A (zh) 纤维肌痛综合征的治疗方法
EP3265443B1 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
JP2018521126A5 (https=)
JP2016513706A (ja) 点眼用製剤
JP2017531012A (ja) Sarmを使用した泌尿器系障害の治療方法
CA2674144A1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
AU2022244467A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
RU2672057C2 (ru) Ингибитор хориоретинальных нарушений
JP2011515406A (ja) 治療用の置換シクロペンタン類
JP2025514548A (ja) カレバスチンの塩及びその用途
US20200030305A1 (en) Local anesthetic-containing acidic emulsion composition
JP2017534658A (ja) プロスタグランジンと一酸化窒素供与体との組み合わせ
JP6588475B2 (ja) 治療用化合物としての新規のep4アゴニスト
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
US20230174510A1 (en) N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof
JP2018534358A (ja) Vegf阻害剤の局所投与による皮膚障害の処置
JP7821740B2 (ja) 代謝異常を治療するためのベンズイミダゾール化合物
WO2025171323A1 (en) Compositions and methods for treating eye conditions
NZ522249A (en) Felbamate derived compounds
WO2017082393A1 (ja) 緑内障予防治療剤
JP2003089637A (ja) アレルギー性眼疾患の治療剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160112